Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.

Abstract: Methods are disclosed herein for treating depression in the subject. A method includes the use of Botulinum toxin to cause paralysis of a facial muscle, such as the depressor anguli oris, procerus, frontalis, orbicularis oculi, or corrugator supercilii muscle to treat depression in the subject.

Abstract: The present invention provides methods and compositions for production of gram-negative bacterial mutants that are defective in intestinal colonization capacity and sensitive to infection by bacteriophage P1. Thus the present invention provides immunogenic compositions for the prevention or attenuation of food- and water-borne illnesses associated with ingestion of bacteria such as enterohemorrhagic Escherichia coli.

Abstract: The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical stability of the prostaglandin active agent so to allow long-term storage also at room temperature.

Abstract: Film coating compositions based on a co-processed mixture of a polyvinyl alcohol-polyether graft polymer and polyvinyl alcohol (component A), a N-vinylpyrrolidone-vinyl acetate copolymer (component B) and pigments (component C).

Abstract: The present invention relates to oligoesters and their use for the creation of additives. Oligoester containing additives and/or oligoesters themselves may be used for formulating pharmaceutical preparations, cosmetics or personal care products such as shampoos and conditioners. These oligoesters are particularly useful for the creation of multi-purpose additives that can impart conditioning, long substantivity and/or UV protection. Individual oligoesters and oligoester mixtures are described.

Abstract: Embodiments include coatings or surface treatments for medical instruments, devices, and/or implants that promote soft tissue healing. More particularly, embodiments relate to treating portions of instruments, devices, and implants where tissue healing is desired with tissue healing promoting treatments.

Abstract: The invention provides articles of manufacture comprising biocompatible nanostructures comprising nanotubes and nanopores for, e.g., organ, tissue and/or cell growth, e.g., for bone, kidney or liver growth, and uses thereof, e.g., for in vitro testing, in vivo implants, including their use in making and using artificial organs, and related therapeutics. The invention provides lock-in nanostructures comprising a plurality of nanopores or nanotubes, wherein the nanopore or nanotube entrance has a smaller diameter or size than the rest (the interior) of the nanopore or nanotube. The invention also provides dual structured biomaterial comprising micro- or macro-pores and nanopores. The invention provides biomaterials having a surface comprising a plurality of enlarged diameter nanopores and/or nanotubes.

Abstract: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

Abstract: The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, an antioxidant, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In some embodiments, the additive is a liquid. In other embodiments, the additive is at least one of a surfactant and a chemical compound, and the chemical compound has one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups.

Abstract: The disclosure concerns altering the mechanical and/or chemical property of a body tissue, particularly an ocular tissue. In specific cases, it concerns altering or stabilizing the shape of the cornea, such as in a subject suffering or at risk for ectasia or keratoconus. In other specific cases, it concerns strengthening the sclera in a subject suffering or at risk for myopia. The invention employs light irradiation of a photoactivatable compound, such as one that applies crosslinking to the tissue, for example.

Abstract: The present invention relates generally to devices and methods for administering one or more active agents to the eye of a human or animal patient in need thereof, and more particularly to devices for application to the cornea which release active agent to the eye in a controlled manner.

Abstract: The present invention is related to improved compositions for reducing serum total and/or LDL cholesterol levels. The compositions are combinations of dietary fiber and plant sterol. The compositions are used as such or more advantageously in food products and comprise one or several fibers, preferably ?-glucan, in combination with one or several plant sterols and/or stanols in their free and/or esterified forms.

Abstract: Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration to mucosal surface, such as oral, gastrointestinal and nasal mucosa. The compositions provided contain one or more mucoadhesive proteins and an agent to be delivered. Methods for delivery of agents using the compositions provided herein are also provided.

Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

Abstract: A matrix formulation for a soft chewable capsule is provided which includes a gel-forming composition, a plasticizer, a polymer modifier, and water. The polymer modifier may be a carboxylic acid or other organic compound that alters the physical and/or chemical properties of the capsule formulation. A chewable soft capsule is also provided, having enhanced organo-leptic and processing properties. An active material may be delivered to a user using this dosage form. A method of forming the chewable soft capsule is also provided.

Abstract: This chewable capsule has an encapsulating shell and a filling contained within the encapsulating shell, in which outer diameter of the above encapsulating shell ranges from 14 mm to 25 mm, and mass of the above encapsulating shell ranges from 10% to 20% of the total mass of the chewable capsule, the quantity of the above filling contained within the above encapsulating shell ranges from 1400 mg to 3000 mg, and gelatin is contained in the above encapsulating shell.

Abstract: Formulations containing imatinib, preferably imatinib mesylate, with high polymorphic stability and the processes for the preparation thereof are disclosed.

Abstract: The invention relates to a sustained release formulation for delivering one or more pharmaceutically active agents. The formulation comprises cross-linked high amylose starch and at least one pharmaceutically active agent, and optionally can be subdivided into smaller dosage forms where the smaller dosage forms have substantially the same sustained release properties as the formulation from which they were derived. The formulations can provide sustained release for up to at least 24 hours, and because of their divisability permits a recipient of the active agent or the person administering the active agent to titrate the dosage of the agent.

Abstract: This invention relates to pharmaceutical compositions containing irbesartan, providing oral formulations with a high relative amount or concentration of irbesartan. In one embodiment, the present invention provides an oral formulation of irbesartan containing greater than 70% w/w irbesartan. In another embodiment, the invention provides an oral formulation of irbesartan which exhibits a dissolution profile according to which greater than about 85% of the Irbesartan is dissolved within about 30 minutes using USP apparatus 2, placing the tablet in 1000 mL of 0.1N hydrochloric acid at 37° C. with paddle speed of 50 rpm. The formulation can optionally contain at least one additional active ingredient.

Abstract: Disclosed are pharmaceutical compositions comprising fixed-dose combinations of a dipeptidyl peptidase-4 inhibitor and metformin, methods of preparing such pharmaceutical compositions, and methods of treating Type 2 diabetes with such pharmaceutical compositions.

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Abstract: A method for the immobilization of bioactive molecules within a polymer substrate to be employed as an oral drug delivery system is provided. A water insoluble carrier matrix can be provided that is water swellable, and biologically active agents can be incorporated. The matrix can be a macromolecular network synthesized by gamma radiation at temperatures between ?78 degrees Celsius to a boiling point of a component elected for polymerization.

Abstract: An object of the present invention is to establish a cell transplantation method which can markedly improve the survival of grafted pluripotent stem cells and the efficiency of cardiomyocyte regeneration in cell therapy using pluripotent stem cells derived from heart tissue and can treat heart disease further effectively. Specifically, according to the present invention, enhancement in the survival of grafted pluripotent stem cells and significant improvement in the efficiency of cardiomyocyte regeneration are achieved by using, in combination, pluripotent stem cells derived from heart tissue and a hydrogel containing a basic fibroblast growth factor (bFGF) in cell therapy for heart disease.

Abstract: An article containing N-acylchitosan is manufactured by a process comprising the steps of providing a mixture containing chitosan and/or N-acylchitosan, and extruding the mixture to form an N-acylchitosan hydrogel. Alternatively, the process comprising the steps of providing a chitosan and/or N-acylchitosan hydrogel, and extruding the hydrogel. An article with a memorized shape is formed by fixing the N-acylchitosan hydrogel in a desired shape, and at least partially drying the fixed hydrogel. A patient is treated by injecting the N-acylchitosan hydrogel.

Abstract: The present invention concerns nanoparticles, compositions comprising the nanoparticles, methods for their production, and methods of using the nanoparticles for the delivery of biologically active agents (e.g., antibiotics or other drugs) to human or non-human subjects. In one embodiment, the nanoparticle is a “surfactant-free” nanoparticle in which the surfactant moiety is covalently attached to the backbone of the polymer.

Abstract: Biodegradable cross-linked particles, as well as related compositions and methods, are disclosed.

Abstract: A cartilage-like biomaterial is bioengineered by using a self-aggregating suspension cell culture with hydrostatic mechanical force without the use of a scaffold or foreign matrix for cell attachment during culture. The cells in suspension culture may be preconditioned prior to application of the hydrostatic mechanical force, such as hydrostatic pressure, for a period of time in the range of about 1 week to about 10 weeks. The cartilage-like biomaterial shares critical structural, phenotype, and functional characteristics with native, intact cartilage tissue.

Abstract: The dried amniotic membrane is produced by drying a fresh amniotic membrane, which envelopes an embryo of an animal including human, and can be used as a substitute membrane for a membrane tissue in a living body; the dried amniotic membrane is dehydrated and dried so that the dried amniotic membrane can be stored in a dry air in a sterile state; when hydrated again by immersing in water or a buffer solution, the amniotic membrane still has an epithelial cell, a basement membrane and a connective tissue which constitute the fresh amniotic membrane. The dried amniotic membrane is useful as a medical substitute membrane for a membrane tissue in a living body such as a dura mater, a meninx, a pericardium, a pleura and a peritoneum.

Abstract: The present invention discloses a surgical cement and a manufacturing method thereof. The surgical cement comprises a cementing component selected form the group of a basic calcium phosphate consisting of tetracalcium phosphate, alpha-tricalcium phosphate, decomposed hydroxyapatite, or a combination thereof; a setting reagent selected form the group of an acidic calcium citrate consisting of monocalcium citrate, dicalcium citrate, or a combination thereof; and water; wherein a weight ratio of the cementing component and the setting reagent ranges from about 1:1 to about 8:1. The surgical cement is bioresorbable and bioactive and is useful in orthopedic, maxillofacial and dental applications. In addition, the surgical cement of this invention has a good flow character and a relatively short setting time.

Abstract: Disclosed is a wood preservative composition comprising micronized copper and copper-amine complex, wherein the copper component of the copper amine complex is from about 5% to about 50% by weight, based upon the total weight of copper in the composition. The copper amine complex serves to avoid wood surface “chalking” that is otherwise attributable to the presence of micronized copper in copper-based slurries used to treat wood products. In addition, the copper-amine complex enhances the antimicrobial efficacy of the composition when used in wood treatment applications by facilitating cell wall penetration of the treated wood.

Abstract: Described are highly concentrated liquid biocidal solutions formed in water from (a) specified bromine sources (e.g., BrCl or mixtures of BrCl and Br2) and (b) alkali metal salt of sulfamic acid and/or sulfamic acid and alkali metal base, wherein the solution contains >160,000 ppm of active bromine. Solutions of this type have been found to have greater stability than a commercially-available solution made from the same components containing 148,600 ppm of active bromine. Also described are new, water-soluble, solid state biocidal products formed by removing the water from solutions made in water from (a) and (b) irrespective of the initial concentration of active bromine. Removal of water can be accomplished by flashing or distillation at reduced pressure or preferably by spray drying. Such solid state products are typically in the form of powders or small particles, but can be compacted into larger forms preferably with the aid of one or more suitable binding agents.

Abstract: This invention relates to an orchid extract of the Brassocattleya marcella Koss variety, as well as the use thereof in compositions such as cosmetic compositions, intended to depigment the skin, in particular to lighten the complexion or to improve the uniformity of the skin coloring, or to correct or attenuate skin spots or hyperpigmented skin areas.

Abstract: The invention provides compositions and methods for treating or preventing infestation of a site with a spider.

Abstract: Disclosed herein are compositions and methods for use of such for clotting blood. In one example, a disclosed composition includes at least Stachys betonica, Achillea millefolium, Marrubium vulgare, and Urtica dioica. Methods of use of the disclosed compositions are also provided, including methods of preventing or inhibiting a nosebleed, bleeding associated with a hemorrhoid or bleeding associated with a wound, such as a cut or abrasion.

Abstract: The present invention relates to a method for inhibition of xanthine oxidase comprising administrating an effective amount of the extracts from Acacia spp.

Abstract: A composition for treating tumors caused by pancreatic, stomach, breast, or liver cancer, leukemia, lung or liver metastasis, and/or arterial aneurysm. The composition comprises in various parts: turtle shell, radix ranunculi ternati, rhizoma dioscoreae bulbiferae, concha arcae, fructus ligustri lucidi, cordyceps sinensis, dwarf lilyturf tuber, Whim brownii, radix astragali, angelica sinensis, radix pseudostellariae, spina date seed, fruit-spike of common selfheal, pericarpium citri reticulatae, costustoot, cape jasmine fruit, radix scrophulariae, radix rehmanniae, rhizoma corydalis, safflower, turmeric root-tuber, cortex moutan, concha ostreae, poria cocoa, herba lysimachiae, the root of red-rooted salvia, isatis indigotica fort, honeysuckle, fructus forsythiae, cortex eucommiae, radix gentianae macrophyllae, radix paeoniae alba, subprostrate sophora, seman platycladi, snakegourd fruit, membrane of chicken gizzard, platycodon grandiflorum, and radix liquiritiae.

Abstract: Disclosed are an Schisandrae fructus extract for inhibition or prevention of influenza and its application, wherein the Schisandrae fructus extract is obtained by water, methanol, or ethanol extraction process and the extract comprises compounds such as schisandrone, benzoylgomisin P, wulignan A1, epigomisin O, epiwulignan A1, and tigloylgomisin P. The extracts and purified compounds of Schisandrae fructus has anti-influenza virus H1N1 and H1N1-TR (a Tamiflu drug resistant virus strain) activities, therefore the extracts and the purified compounds of Schisandrae fructus can be applied as an inhitibory agent of a pharmaceutical composition for treatment or prevention agent for influenza infection.

Abstract: A composition includes a first component containing phospholipids and a second component encapsulating the first component. The composition includes between about 10% and about 80% by weight phospholipids. The composition may be used in chewing gum to provide a gum cud that does not adhere to concrete and does not dissolve in the mouth while chewing.

Abstract: A process for preparation of starchy foods prior to cooking to reduce formation of acrylamide is described. The process uses microorganisms to metabolize sugars in the food sufficiently to reduce formation of the acrylamide. The foods include fried and baked starchy foods including potato chips, cereals, breads, tortilla chips, pretzels, crackers and the like.

Abstract: Described are dough compositions and methods of making dough compositions, the dough compositions being chemically leavened and being prepared from ingredients that include a low temperature inactive yeast and a yeast inhibitor; the methods include inactivating the low temperature inactive yeast to inhibit the metabolic activity of the yeast as desired; the compositions and methods can be used, e.g., to prepare refrigerated dough products.

Abstract: A method for producing a stable beverage preserved with sorbic acid. A beverage syrup is diluted and sorbate is simultaneously introduced into the diluted syrup to form the beverage.

Abstract: A process for producing a palm oil product comprises: (i) partial crystallization of a palm oil or fraction thereof in the absence of a solvent; (ii) mixing the partially crystallized palm oil or fraction with a solvent; (iii) crystallizing the resulting mixture to a greater extent; and (iv) separating the resulting solid from the liquid in a separator, wherein the partially crystallized palm oil or fraction thereof that is formed in (i) is directly mixed with solvent in (ii) without separation of solids from liquids prior to (ii).

Abstract: A brewing piston for infusion preparation, including a head associated with a filtering element, and a lateral surface having a first gasket in proximity to the head and a second gasket at a distance from the first gasket. The brewing piston includes a first conduit connected to the head and arranged to inject a liquid for infusion preparation, and a second conduit connected to the lateral surface between the gaskets and arranged to inject the liquid between the first gasket and the second gasket during infusion preparation. The piston is arranged to limit or avoid leaks in a machine for infusion preparation. Also included is a machine using the piston and a method of limiting or avoiding leaks in a machine for infusion preparation.

Abstract: The invention relates to a wet grinding method for producing sterol formulations having good wettability. According to said method, a) an additive selected from the group consisting of proteins, proteinaceous adjuvants, carbohydrates, cellulose derivatives, sugar alcohols, fruit concentrates and vegetable concentrates is dissolved or dispersed in water or in an aqueous suspension medium, b) sterol and/or stanol particles having a median particle size of at least 1 mm are added to this solution/dispersion, c) the dispersion thus obtained is homogenized and size-reduced in a mill that works according to the rotor/stator principle, and d) is then optionally dried, with the proviso that the sterol and/or stanol particles are present in the final formulation with a particle size distribution of D90% of not more than 50 ?m.

Abstract: An improved processing method and system for producing tomato paste and other food products affected by viscosity. Tomatoes are processed into tomato juice. The juice is provided to a decanter that separates or fractionates the juice into two portions—a thicker, more viscous cake portion and a thinner, less viscous serum portion. The serum portion is concentrated by removing a portion of water using an evaporator such as a thin film or juice evaporator. The cake portion can be concentrated if necessary with a drier. The serum and cake portions are re-combined to produce a tomato paste having improved color, texture, flavor and nutrition.

Abstract: The present invention is directed to a pharmaceutical preparation for oral application for treatment of fish, in particular for vaccination of fish of the salmon family and other fish having a comparable digestive system against bacterial and/or viral infections, in particular against VHS and IHN. The invention is also directed to a method for producing the preparation.

Abstract: The invention provides methods of purifying Rebaudioside D from the Stevia rebaudiana Bertoni plant extract along with Rebaudioside A. The methods are useful for producing high purity Rebaudioside D and Rebaudioside A. The invention further provides a low-calorie ice cream containing the purified Rebaudioside D and a process for making the low-calorie ice cream containing the purified Rebaudioside D.

Abstract: The invention provides methods of purifying Rebaudioside D from the Stevia rebaudiana Bertoni plant extract along with Rebaudioside A. The methods are useful for producing high purity Rebaudioside D and Rebaudioside A. The invention further provides a low-calorie yogurt containing the purified Rebaudioside D and a process for making the low-calorie yogurt containing the purified Rebaudioside D.

Abstract: The invention provides methods of purifying Rebaudioside D from the Stevia rebaudiana Bertoni plant extract along with Rebaudioside A. The methods are useful for producing high purity Rebaudioside D and Rebaudioside A. The invention further provides a low-calorie table top tablet containing the purified Rebaudioside D and a process for making the low-calorie table top tablet containing the purified Rebaudioside D.